Navigation Links
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
Date:12/4/2007

NEW HAVEN, Conn., Dec. 4 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq Capital Market: VION) today announced the start of an investigator-sponsored Phase I clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with hematopoietic cell transplant (HCT) in patients with various advanced hematologic malignancies. The trial is being conducted under the direction of Roy Jones, M.D., Ph.D., a professor in the Department of Stem Cell Transplantation at The University of Texas M.D. Anderson Cancer Center.

The objective of the trial is to define the maximum tolerated dose (MTD) of Cloretazine(R) (VNP40101M) when given to patients of 18 to 65 years of age with poor-prognosis leukemia, lymphoma, and Hodgkin's disease who are undergoing either an allogeneic or autologous HCT.

Ann Cahill, Vice President of Clinical Development, commented, "Both patients and physicians are searching for ways to improve outcomes after stem cell transplantation. Patients with advanced disease are particularly in need of new therapies." Ms. Cahill concluded, "We are hopeful that Cloretazine(R) (VNP40101M) can make a contribution in the stem cell transplant setting."

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials spon
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014  ResMed (NYSE: RMD ) ... Exchange program, a comprehensive suite of software and ... other health care providers. ResMed ... patient information. It integrates valuable sleep and respiratory ... management platforms with customers, in-house or third-party electronic ...
(Date:10/20/2014)... 20, 2014   BioNano Genomics announced today achievement ... to collect human data at 30X depth, sufficient for a ... new capability was established and demonstrated for the IrysChip TM ... System and will be rolled out to BioNano,s ... be showcasing this advancement at the American Society for ...
(Date:10/20/2014)...   Taiho Oncology, Inc. , a subsidiary ... ), announced that the U.S. Food and ... TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an ... treatment of refractory metastatic colorectal cancer (mCRC), and ... submission to the FDA. According to the American ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... 19, 2011 Enhanced Equity Fund (EEF), a healthcare-focused ... investment in MedTest DX, Inc. (MedTest), a medical diagnostic ... to purchase the chemistry diagnostics business from Polymedco, Inc. ... of EEF.  Terms were not disclosed. "EEF ...
... 2011 Wound Management Technologies, Inc., (OTCQB: WNDM | ... the publication of an interview of its President Deborah ... of interviews with CEOs and CFOs of publicly traded ... conducted by Lynn Fosse, Senior Editor, CEOCFOInterviews.com include why ...
Cached Medicine Technology:Enhanced Equity Fund and James White Invest in MedTest DX, Inc. 2WNDM President Interviewed; Discusses 2011 Outlook and Beyond 2WNDM President Interviewed; Discusses 2011 Outlook and Beyond 3
(Date:10/20/2014)... 2014 The Advocator Group, LLC ... the American Foundation for Suicide Prevention’s (AFSP) Out of ... a not-for-profit organization that hosts hundreds of community walks ... events are used to help understand and prevent suicide ... relationships as well. , The Advocator Group shares ...
(Date:10/20/2014)... October 20, 2014 T.E.N., a ... firm, announced today that William H. Murray, renowned ... 2014 ISE® Luminary Leadership Award winner. Presented annually, ... of an outstanding leader and industry practitioner for ... in advancing the information security industry. , Formerly ...
(Date:10/20/2014)... JZ Fitness, an independently operated wellness ... programming, authorship, international lecturing and community wellness, created by ... release of the JZ Fitness nutrition app, available on ... thousands of individuals on nutrition, Jenn Zerling (“JZ”) has ... require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 AttorneyOne.com, a ... the latest information from the FDA on Sit and ... October 10 not to purchase or use Sit and Slim ... and Slim II is promoted as weight loss product on ... removed from the market in 2010 for safety reasons, can ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in the ... Every Body Walk! campaign by Kaiser Permanente. Every ... to be more active outside of the workplace. This ... end of September, was a friendly competition between organizations across ... companies gave their staff pedometers and each day, for the ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2
... State University College of Nursing & Healthcare ... national Healthcare Innovation Challenge(R) ( http://healthcare.innovationchallenge.com ) in ... a firm that helps organizations run idea competitions. ... January 20 to May 1, 2009, features competition ...
... health care highly as part of efforts to stem ... reforming health care as one of the top priorities ... national survey conducted by researchers from the Kaiser Family ... Americans rank helping the newly unemployed afford health insurance ...
... reimburses patients and physicians who have been shortchanged ... American Medical Association (AMA), along with the Medical Society ... State Medical Association, claims victory with the settlement agreement ... The $350 million settlement marks the largest monetary settlement ...
... 15 The $800 million settlement that Eli,Lilly and Company ... settle civil False Claims,Act charges related to allegedly false or ... traced to the courageous stands taken by,employee whistleblowers, according to ... The company,s settlement with the federal government, which also ...
... The Procter & Gamble,Company (NYSE: PG ... -- Mariano Martin, (56), global customer ... 33 years of service. He will step,down from his ... focus on working,closely with his successor to ensure a ...
... 15 In a lawsuit pending in Wayne County,Circuit ... OmniCare, a,once-large HMO servicing Medicaid recipients, several major Detroit ... claim for $75 Million in,damages from United American Healthcare, ... In their filing, the Provider Creditors ...
Cached Medicine News:Health News:Arizona State University Nursing and Idea Crossing Partner to Conduct First National Healthcare Innovation Challenge 2Health News:Health provisions among public's top priorities for economic stimulus 2Health News:Health provisions among public's top priorities for economic stimulus 3Health News:Health provisions among public's top priorities for economic stimulus 4Health News:Health provisions among public's top priorities for economic stimulus 5Health News:AMA Claims Victory With Record Breaking Settlement in Case Against Insurer 2Health News:Whistleblowers' Complaints Lead Eli Lilly to Pay $800 Million to Settle Civil Medicaid Fraud Charges, According to Berg & Androphy 2Health News:Procter & Gamble Announces Organizational Changes 2Health News:Detroit Area Hospitals Seek $75 Million from United American HealthCare Arising out of its Management of the Liquidated OmniCare HMO 2
... Fast - Powerful g-Force for Fast and Optimal ... rpm (18,000 x g) Ideal for pelleting of ... Fits on crowded bench or in a cold ... aerosol-tight, autoclavable fixed-angle rotor Quiet operation ...
... EXD explosion-proof laboratory floor model centrifuge meets ... EXD is suitable for use in Class ... "atmospheres containing gasoline, petroleum, naphtha, benzol, lacquer, ... these specifications is so strict that the ...
Inquire...
... The XCell line of mini-cells ... simple sturdy and convenient. The tradition ... Mini-Cell. The incorporation of a gel ... rear wedge used on earlier models ...
Medicine Products: